Accession Number:

ADA359213

Title:

Recombinant Vaccine Strategies for Breast Cancer Prevention

Descriptive Note:

Annual rept 1 Oct 97-30 Sep 98

Corporate Author:

JOHNS HOPKINS UNIV BALTIMORE MD

Personal Author(s):

Report Date:

1998-10-01

Pagination or Media Count:

23.0

Abstract:

Exciting new findings in autoimmune disease and cancer have led to the realization that a large set of antigenic determinants of the self have not induced self-tolerance. These peptide determinants could provide target structures for autoimmune attack as well as antitumor immune responses. We hypothesized that vaccine strategies can be devised that specifically generate an immune response against breast ductal epithelial cells. Since the overwhelming majority of breast tumors arise in these cells, destroying these cells prior to the development of neoplasia will effectively prevent cancer. We are attempting to augment the immune response to the breast-specific antigen, HER-2neu, which is expressed by mammary tissue in HER-2lneu transgenic mice prior to mammary tumor development, by enhancing the T cell response using selected vectors that may alter antigen processing, thereby influencing antigen-specific immunity. We have evaluated vaccinia constructs that express antigen alone or together with the cytokine GM-CSF, to determine if this immunity can be further enhanced. In our preliminary studies, we have found that this vaccinia approach is superior to vaccination with plasmid DNA either intramuscularly or via gene gun delivery. We will next compare this vaccinia approach with vaccinia carrying the HER2Ineu gene along with the lysosomal targeting molecule, LAMP-i. This study will provide a paradigm for novel vaccine approaches to breast cancer prevention.

Subject Categories:

  • Medicine and Medical Research
  • Pharmacology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE